Samsung Bioepis Receives the US FDA’s Approval for Multi-Dose Vial of Ontruzant (biosimilar, trastuzumab)

 Samsung Bioepis Receives the US FDA’s Approval for Multi-Dose Vial of Ontruzant (biosimilar, trastuzumab)

Samsung Bioepis Receives the US FDA’s Approval for Multi-Dose Vial of Ontruzant (biosimilar, trastuzumab)Samsung Bioepis Receives the US FDA’s Approval for Multi-Dose Vial of Ontruzant (biosimilar, trastuzumab)

Shots:

  • The US FDA has approved the 420 mg multi-dose vial of Ontruzant (trastuzumab-dttb), a biosimilar referencing Herceptin (trastuzumab) and will be marketed & distributed by Merck in the US
  • On Feb 05, 2020, Merck has announced the spin-off its biosimilar business and will continue to support the commercialization of Ontruzant until the spinoff, which is anticipated to be held in H1’21
  • Ontruzant (150 mg, single-dose vial) is an approved therapy for HER2-overexpressing BC, mBC and mGC or gastroesophageal junction adenocarcinoma in patients with prior treatment for metastatic disease

Click here ­to­ read full press release/ article | Ref: Samsung Bioepis | Image: Samsung Bioepis

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post